(Q38254050)

1 September 2017

1 reference

title

The Warburg effect: molecular aspects and therapeutic possibilities (English)

1 reference

1 September 2017

4

Tom C Karagiannis

1 reference

1 September 2017

3

Katherine Ververis

1 reference

1 September 2017

2

Stephanie M Tortorella

1 reference

1 September 2017

Hanh Ngo

1

1 reference

1 September 2017

1 April 2015

1 reference

Molecular Biology Reports

1 September 2017

1 reference

1 September 2017

42

1 reference

1 September 2017

4

1 reference

1 September 2017

825-834

1 reference

https://scigraph.springernature.com/pub.10.1007/s11033-014-3764-7

1 September 2017

0 references

cites work

Otto Heinrich Warburg, 1883-1970

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

On the Origin of Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Understanding the Warburg effect: the metabolic requirements of cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

"Wages of fear": transient threefold decrease in intracellular ATP level imposes apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Regulation of glutaminase activity and glutamine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Akt-dependent transformation: there is more to growth than just surviving

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

c-Myc transactivation of LDH-A: implications for tumor metabolism and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

The interplay between MYC and HIF in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

TIGAR, a p53-inducible regulator of glycolysis and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

p53 regulates mitochondrial respiration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

New aspects of the Warburg effect in cancer cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

ERRalpha: a metabolic function for the oldest orphan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

The metabolic regulator ERRα, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

The biology of cancer: metabolic reprogramming fuels cell growth and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Immunity, Inflammation, and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

From tumor cell metabolism to tumor immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Lactic acid and acidification inhibit TNF secretion and glycolysis of human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Tumor-derived lactic acid modulates dendritic cell activation and antigen expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Oxidative phosphorylation induces de novo expression of the MHC class I in tumor cells through the ERK5 pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Hypoxia, glucose metabolism and the Warburg's effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Chromatin structure and DNA double-strand break responses in cancer progression and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Epigenetic regulation of centromeric chromatin: old dogs, new tricks?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

The methyl-CpG binding domain and the evolving role of DNA methylation in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Chromatin modification and epigenetic reprogramming in mammalian development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Translating the Histone Code

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Epigenetic regulation of the cell type-specific gene 14-3-3sigma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Regulation of 14-3-3sigma expression in human thyroid carcinoma is epigenetically regulated by aberrant cytosine methylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Ubiquitous and tenacious methylation of the CpG site in codon 248 of the p53 gene may explain its frequent appearance as a mutational hot spot in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Prooxidant states and tumor promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Metabolic defects provide a spark for the epigenetic switch in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Sirtuins as potential targets for metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Mechanisms involved in the regulation of histone lysine demethylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Glucose metabolism in cancer. Evidence that demethylation events play a role in activating type II hexokinase gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-d-glucose in tumor cells treated under hypoxic vs aerobic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Dichloroacetate in the treatment of lactic acidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Dichloroacetate induces apoptosis in endometrial cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Dichloroacetate treatment for mitochondrial cytopathy: long-term effects in MELAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. The Dichloroacetate-Lactic Acidosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Nerve conduction changes in patients with mitochondrial diseases treated with dichloroacetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3764-7

Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention

21 January 2018

1 reference

12 December 2020

Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells

1 reference

12 December 2020

Differential DNA methylation of the p16 INK4A/CDKN2A promoter in human oral cancer cells and normal human oral keratinocytes

1 reference

12 December 2020

The concept of immunological surveillance

1 reference

12 December 2020

Effects of PDH activation by dichloroacetate in human skeletal muscle during exercise in hypoxia

1 reference

12 December 2020

Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release

1 reference

12 December 2020

Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc

1 reference

12 December 2020

Inhibitory effect of tumor cell-derived lactic acid on human T cells

1 reference

12 December 2020

Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia.

1 reference

12 December 2020

Effects of dichloroacetate infusion on human skeletal muscle metabolism at the onset of exercise

1 reference

12 December 2020

Localization of the primary metabolic block produced by 2-deoxyglucose

1 reference

12 December 2020

Complete and tissue-independent methylation of CpG sites in the p53 gene: implications for mutations in human cancers.

1 reference

12 December 2020

Metabolic targeting as an anticancer strategy: dawn of a new era?

1 reference

12 December 2020

Efficacy of dichloroacetate as a lactate-lowering drug

1 reference

12 December 2020

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death

1 reference

12 December 2020

Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients

1 reference

12 December 2020

10.1007/S11033-014-3764-7

Identifiers

DOI

1 reference

PubMed ID

25253100

Dimensions Publication ID

1 September 2017

1030850242

0 references

Fatcat ID

release_2o7wcek5hna4tgq3rma7ozicia

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2o7wcek5hna4tgq3rma7ozicia

24 November 2022

mapped directly with Wikidata item

PubMed ID

25253100

1 reference

PubMed ID

25253100